Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo (VEP-COV)
COVID19

About this trial
This is an interventional prevention trial for COVID19 focused on measuring COVID19, prevention, Povidone Iodine, Low and middle income countries
Eligibility Criteria
Inclusion Criteria:
- Age: 15-90 years
- Either gender
- Patients diagnosed with COVID-19 disease by RT-PCR
- Have confirmed COVID-19 symptoms and symptom onset within the past 10 days
- Capable of using a nasal spray device and perform nasal irrigation required by the study
- Willing to participate
Exclusion Criteria:
- Patient with known sensitivity to PVP-I aqueous antiseptic solution or any of its listed excipients
- Previously diagnosed thyroid disease
- Patients with chronic renal failure (stage ≥3 by estimated Glomerular Filtration rate (eGFR) Modification of Diet in Renal Disease( MDRD)
- Patients with acute renal failure (KDIGO ≥stage 2: creatinine ≥2 X baseline)
- Pregnant and lactating mother
- Current requirement for invasive or non-invasive ventilation or planned within next 6 hours.
Sites / Locations
- Dhaka Medical College
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Placebo Comparator
PVP-I 0.4% NI
PVP-I 0.5% NI
PVP-I 0.6% NI
PVP-I NS 0.5% NS
PVP-I 0.6% NS
DW NI
DW NS
Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
Arm-6 will receive distilled water through nasal irrigation
Arm-7 will receive distilled water through nasal spray